Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal ...

“narrowly” missed showing a statistically significant improvement over Humira (adalimumab) in psoriatic arthritis (PsA) patients. Specifically, Cosentyx was unable to top Humira on the ACR 20 ...

Biotech stock MoonLake Immunotherapeutics rose Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira in a 24-week study. Please watch the video at ...

For patients with psoriatic arthritis, switching directly from adalimumab ... and efficacy of switching directly from adalimumab (Humira, AbbVie) to tofacitinib (Xeljanz, Pfizer) in PsA, Gladman ...

UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement ... Medscape Medical News, July 24, 2024 GRAPPA 2024 Psoriatic Arthritis Treatment Failure Tied to Key Factors Comorbidities ...

NICE has issued a final appraisal determination recommending Celgene's Otezla for adults with active psoriatic arthritis ... led by AbbVie's Humira. NICE'S change of heart means Otezla can ...

2024 UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement Lists Next Year UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug ...

Humira, another immunosuppressive drug to treat psoriatic arthritis, is the only drug listed as a major interaction among the ...

Three other biologics — adalimumab (Humira; Abbott), etanercept (Enbrel ... which has recently been approved for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...